Contraindications for GLP-1 Receptor Agonists
GLP-1 receptor agonists are absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), and in those with a history of serious hypersensitivity reactions to the drug. 1, 2
Absolute Contraindications
The following are firm contraindications where GLP-1 RAs must not be prescribed:
- Personal or family history of medullary thyroid carcinoma - This stems from rodent studies showing thyroid C-cell tumors, though human relevance remains unproven 2, 3, 4
- Multiple endocrine neoplasia syndrome type 2 (MEN2) 1, 2, 4
- History of serious hypersensitivity reaction to the specific GLP-1 RA 1
- Severe renal impairment or ESRD - This applies specifically to exenatide and lixisenatide only 1, 4
Important distinction: Longer-acting agents (semaglutide, liraglutide, exenatide ER, dulaglutide) carry the MTC/MEN2 contraindication, while twice-daily exenatide and lixisenatide do not 2, 3. However, the FDA has clarified that patients taking GLP-1 RAs do not require routine monitoring for medullary thyroid carcinoma (e.g., calcitonin levels) 2.
Renal Function Considerations
Renal impairment creates agent-specific restrictions:
- Exenatide: Not recommended if eGFR <30 mL/min 4
- Lixisenatide: Use with caution if eGFR <30 mL/min 4
- Liraglutide and semaglutide: Can be used with caution in severe renal impairment or ESRD 1
- Dulaglutide: Can be used with dose adjustment in renal impairment 4
Clinical Cautions (Not Absolute Contraindications)
While not contraindications, these situations warrant careful consideration:
History of pancreatitis: Although a causal relationship has not been established 2, 3, prescribing information recommends considering other antihyperglycemic therapies in patients with prior pancreatitis 2. If pancreatitis is suspected during treatment, discontinue immediately and do not restart if confirmed 3.
Gastroparesis or prior gastric surgery: Shorter-acting agents delay gastric emptying and are not recommended in clinically meaningful gastroparesis 1. This effect is usually transient with longer-acting agents 1. Care should be taken in patients with prior gastric surgery 1.
Diabetic retinopathy: Semaglutide has been associated with diabetic retinopathy complications, potentially related to rapid glucose and A1C reductions 1.
Hypoglycemia risk: When combined with insulin or insulin secretagogues (sulfonylureas), dose reduction of these agents may be required 1.
Common Pitfalls to Avoid
- Do not confuse agent-specific renal restrictions - Not all GLP-1 RAs have the same renal limitations
- Do not routinely screen for MTC - The FDA explicitly states monitoring is not needed 2
- Do not automatically exclude patients with prior pancreatitis - While caution is warranted, it is not an absolute contraindication; the evidence for causation is weak 2, 5
- Do not assume all GLP-1 RAs carry the MTC warning - Twice-daily exenatide and lixisenatide are exceptions 2
The evidence consistently shows that serious contraindications are limited primarily to thyroid cancer history and MEN2, with agent-specific renal restrictions. Most other concerns represent cautions requiring clinical judgment rather than absolute prohibitions.